Sareum (LON:SAR) Posts Quarterly Earnings Results

Sareum (LON:SAR) announced its quarterly earnings data on Tuesday. The company reported GBX (0.90) (($0.01)) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

Sareum Stock Performance

Shares of SAR traded up GBX 1.15 ($0.01) during mid-day trading on Thursday, reaching GBX 13.15 ($0.17). The stock had a trading volume of 1,258,110 shares, compared to its average volume of 425,572. The business has a fifty day moving average of GBX 17.82 and a 200 day moving average of GBX 23.19. The firm has a market cap of £16.43 million, a price-to-earnings ratio of -3.11 and a beta of -1.08. Sareum has a 12 month low of GBX 10 ($0.13) and a 12 month high of GBX 52.50 ($0.68).

Insider Activity

In other Sareum news, insider Stephen Parker purchased 84,033 shares of the stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average cost of GBX 12 ($0.15) per share, with a total value of £10,083.96 ($12,983.08). Insiders own 5.02% of the company’s stock.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.